Literature DB >> 4057084

Sensitization to repeated enkephalin administration into the ventral tegmental area of the rat. II. Involvement of the mesolimbic dopamine system.

P W Kalivas.   

Abstract

In the preceding report it was shown that daily microinjection with the enkephalin analog, D-Ala2-Met5-enkephalinamide (DALA), into the ventral tegmental area (VTA) results in a progressive increase in spontaneous motor activity. In this study it was found that the enhanced behavioral response was associated with a greater increase in dopamine metabolism in the nucleus accumbens and striatum after acute DALA administration. However, daily injection with either DALA or saline did not alter the steady-state levels of dopamine or its metabolites. Haloperidol did not block the development of an augmented behavioral response. Rats pretreated with daily intra-VTA injections of DALA had a significantly greater motor response to amphetamine, i.p. or neurotensin, intra-VTA, when compared with rats pretreated with daily saline. However, the motor effects of caffeine or intraaccumbens injection with dopamine were not altered by daily injections. These data support the idea that daily intra-VTA injection with DALA results in an increased responsiveness of mesolimbic dopamine neurons to excitatory pharmacological stimuli.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4057084

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Locomotor-activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections.

Authors:  D C Hoffman; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Expression of morphine-conditioned hyperactivity is attenuated by naloxone and pimozide.

Authors:  J L Neisewander; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine.

Authors:  B T Lett
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Self-administered heroin and cocaine combinations in the rat: additive reinforcing effects-supra-additive effects on nucleus accumbens extracellular dopamine.

Authors:  James E Smith; Conchita Co; Michael D Coller; Scott E Hemby; Thomas J Martin
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

5.  Lack of cross-sensitization between the locomotor-activating effects of bromocriptine and those of cocaine or heroin.

Authors:  D C Hoffman; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Selective enhancement of emotional, but not motor, learning in monoamine oxidase A-deficient mice.

Authors:  J J Kim; J C Shih; K Chen; L Chen; S Bao; S Maren; S G Anagnostaras; M S Fanselow; E De Maeyer; I Seif; R F Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

7.  Pharmacological specificity of enhanced sensitivity to naltrexone in rats.

Authors:  C W Schindler; S R Goldberg; J L Katz
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Transport of dopamine at the blood-brain barrier of the guinea pig: inhibition by psychotropic drugs and nicotine.

Authors:  C L Martel; J B Mackic; J D Adams; J G McComb; M H Weiss; B V Zlokovic
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

9.  Changes in brain monoamines and their metabolites during and after hemorrhagic shock in the rat.

Authors:  T Mizobe; C Okuda; H Demura; H Tanaka; T Sawa; M Miyazaki; K Kuriyama
Journal:  J Anesth       Date:  1990-04       Impact factor: 2.078

10.  Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system.

Authors:  Mario E Alburges; Amanda J Hoonakker; Glen R Hanson
Journal:  Eur J Pharmacol       Date:  2007-07-24       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.